Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03501550 · ClinicalTrials.gov registry record · Phase 2
Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)
A Phase 2 study, sponsored by Cocrystal Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03501550 is a Phase 2 study that has completed, run by Cocrystal Pharma. The registered enrollment target is 12 participants.
The verdict
NCT03501550, a Phase 2 study, has completed, sponsored by Cocrystal Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic hepatitis C (HCV) genotype 1 (GT1) infection
Interventions
- DRUG SOF/VEL
- DRUG CDI-31244
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-06-26 |
| Est. Completion | 2019-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03501550
The ClinicalTrials.gov registry entry for NCT03501550 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cocrystal Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SOF/VEL is the first listed.
NCT03501550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03501550 about?
NCT03501550 is a clinical study titled "Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)". Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic hepatitis C (HCV) genotype 1 (GT1) infection
What is the current status of trial NCT03501550?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2018-06-26. Estimated completion is 2019-06-07.
What interventions are being tested in trial NCT03501550?
The interventions under investigation include: SOF/VEL (DRUG), CDI-31244 (DRUG).
Who is sponsoring clinical trial NCT03501550?
This trial is sponsored by Cocrystal Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.